Quarterly report pursuant to Section 13 or 15(d)

Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details)

v3.23.3
Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2020
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Aug. 31, 2023
Mar. 31, 2023
Feb. 28, 2023
Jan. 01, 2023
Oct. 07, 2022
Dec. 31, 2021
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Research and development expense   $ 13,787,000 $ 8,216,000 $ 38,019,000 $ 26,900,000              
Upfront Payment             $ 500          
Accrued and Other Current Liabilities                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Expenses       200,000                
License and Service [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Upfront Payment               $ 1,200,000        
License Agreement                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Obligation to be paid   2,000,000   $ 2,000,000                
Payment term       3 years                
Payment commencement date       2018-08                
License maintenance fee $ 33,000     $ 10,000                
Total milestone payments       21,000,000                
Amounts due to agreement   0   0                
Sponsored Research Agreements                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Obligation to be paid   12,560,000   12,560,000                
Master Translational Research Services Agreement                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Research and development expense   668,000 $ 333,000 2,873,000 $ 1,934,000              
Remaining research and development expense to be incurred       643,000                
Oxford Biomedica                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Obligation to be paid   5,000   5,000               $ 4,000,000
Research and development expense           $ 1,100,000            
Expenses   342   920                
Nanjing IASO Biotherapeutics Co., Ltd. [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Upfront Payment   $ 162,000,000   162,000,000             $ 2,500,000  
Autolus Holdings [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Upfront Payment               $ 100,000 $ 800,000 $ 1,200,000    
Autolus Holdings [Member] | Maximum [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Total milestone payments       15,000,000                
Autolus Holdings [Member] | Maximum [Member] | License and Service [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Total milestone payments       $ 12,000,000